
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The American Journal of Managed Care
almost 25 years ago
Effects of Restrictive Formularies in the Ambulatory Care Settingalmost 25 years ago
The Generalist's Patient and the Subspecialistalmost 25 years ago
Issues in Pooling Administrative Data for Economic Evaluation




